Exosomes Pipeline constitutes 80+ key companies continuously working towards developing 100+ Exosomes treatment therapies, analyzes DelveInsight.
Exosomes Overview:
Exosomes are tiny extracellular vesicles (30–150 nm) surrounded by a phospholipid bilayer, released by both eukaryotic and prokaryotic cells to support intercellular communication. Once thought to be cellular waste carriers, they are now known to transport proteins, nucleic acids, and metabolites, playing key roles in regulating various biological processes.
Exosomes influence immune responses, infections, pregnancy, neurological and cardiovascular diseases, and cancer progression by delivering molecular cargo to target cells. Their ability to modulate intracellular pathways makes them promising tools in therapeutic applications, especially for conditions like cancer and neurodegenerative disorders. They can be engineered to deliver therapeutic agents—including siRNAs, antisense oligonucleotides, drugs, and immune modulators—with targeted precision.
Therapeutically, exosomes serve multiple roles: as biomarkers for diagnosis, vehicles for drug delivery, standalone therapeutic agents, and immunomodulators. By mediating cell-to-cell communication through active biomolecules such as lipids, proteins, RNAs, and cytokines, exosomes hold significant potential in the diagnosis, treatment, and monitoring of various diseases.
Request for a detailed insights report on Exosomes pipeline insights
"Exosomes Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Exosomes Therapeutics Market.
Key Takeaways from the Exosomes Pipeline Report
-
DelveInsight’s Exosomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment.
-
In January 2025, NurExone Biologic announced the acquisition of a master cell bank from a U.S. manufacturer, marking a significant step toward ensuring a stable and scalable supply chain for producing exosome-based therapies to meet clinical and patient treatment needs.
-
In July 2024, Aruna Bio secured a U.S. patent for the composition of matter for neural exosomes designed to deliver therapeutics to the brain.
-
That same month, ILIAS Biologics received the final clinical study report (CSR) for ILB-202 following a Phase I clinical trial completed in Australia in November 2023.
-
In April 2024:
- Biological Dynamics joined the growing number of customers utilizing the ExoVerita Pro instrument, an automated and cost-efficient exosomal enrichment platform.
- EXO Biologics raised up to EUR 16 million in Series A funding to advance exosome therapeutic development and clinical supply.
- ExoXpert entered a strategic partnership with Neucore Bio to leverage ExoXpert's platform for evaluating advanced exosome loading techniques.
- INOVIQ and Promega signed a global supply and distribution agreement for EXO-NET, following a co-marketing agreement established the previous year.
-
In March 2024, VivaZome Therapeutics and La Trobe University initiated a collaboration to investigate the therapeutic potential of extracellular vesicles in stroke models, led by Professor Chris Sobey.
-
Key Exosomes companies such asMiltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others are evaluating new drugs for Exosomes to improve the treatment landscape.
-
Promising Exosomes pipeline therapies in various stages of development include Brentuximab vedotin, Abexinostat, RNK05047, BMF-219, ADI-001, THOR-707, and others.
Exosomes Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Exosomes Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Exosomes market.
Download our free sample page report on Exosomes pipeline insights
Exosomes Emerging Drugs
-
CAP-1002: Capricor Therapeutics
-
EXO-CD24: Nano24
-
AGLE-102: Aegle Therapeutics
-
Progenza: Cambium Bio
-
EV-101: EV Therapeutics
Exosomes Companies
Over 80 prominent companies are actively working on exosome-based therapies. Among these, Capricor Therapeutics has drug candidates that have reached the most advanced stage of development, Phase III clinical trials.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Exosomes Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Exosomes Therapies and Key Companies: Exosomes Clinical Trials and advancements
Exosomes Pipeline Therapeutic Assessment
• Exosomes Assessment by Product Type
• Exosomes By Stage
• Exosomes Assessment by Route of Administration
• Exosomes Assessment by Molecule Type
Download Exosomes Sample report to know in detail about the Exosomes treatment market @ Exosomes Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Exosomes Current Treatment Patterns
4. Exosomes - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Exosomes Late-Stage Products (Phase-III)
7. Exosomes Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Exosomes Discontinued Products
13. Exosomes Product Profiles
14. Exosomes Key Companies
15. Exosomes Key Products
16. Dormant and Discontinued Products
17. Exosomes Unmet Needs
18. Exosomes Future Perspectives
19. Exosomes Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Exosomes Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
